The Skyway Study for Soticlestat

A Clinical Trial Open to Those With Seizures Associated with LGS

The Skyway Study is a Phase 3 clinical research study of an investigational medication for children, teens, and adults diagnosed with Lennox-Gastaut Syndrome (LGS) who are currently using 0-3 anti-seizure medications to manage symptoms and are still experiencing seizures. The investigational medication, Soticlestat, works differently than currently approved medications and is being tested as an add-on therapy in the clinical research study.

The goal of the Skyway Study is to assess the effectiveness, tolerability, and safety of the investigational medication when taken with other anti-seizure treatments.

Watch Now: Overview of Solticlestat for LGS

Presented by: Michael Chez, MD, Pediatric Epileptologist, Sutter Health, California

*Dr. Michael Chez is a Pediatric Epilepsy Expert and regularly treats LGS patients. This video was recorded in early 2022 at the request of the LGS Foundation to provide information to our family members about this medication. The Foundation does not endorse this or any product and is here only to provide information relevant to patient families. 

Additional Information:

View the Skyway Study Brochure

Watch the Skyway Study Video

Visit the Skyway Study Clinical Trial Website

The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.

Updated: 7/27/2023